ReviewAmerican journal of physiology. Renal physiology2015
Obesity and renovascular disease.
Review in American journal of physiology. Renal physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Epicardial and liver fat implications in albuminuria: a retrospective study.Cardiovascular diabetology · 2024Article
- Recent advances in the treatment of patients with obesity and chronic kidney disease.Annals of medicine · 2023Review
- Donor obesity and weight gain after transplantation: two still overlooked threats to long-term graft survival.Clinical kidney journal · 2023Review
- Anti-Obesity Effects of Formulated Biscuits Supplemented with Date's Fiber; Agro-Waste Products Used as a Potent Functional Food.Nutrients · 2022Article
- Single-cell profiling of vascular endothelial cells reveals progressive organ-specific vulnerabilities during obesity.Nature metabolism · 2022Article
- Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
- Article
- A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management.Frontiers in medicine · 2021Review
- Article
- Importance of the commissural nucleus of the solitary tract in renovascular hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2019Article
- Assessing Microvascular Function in Humans from a Chronic Disease Perspective.Journal of the American Society of Nephrology : JASN · 2017Review
- The protective effect of human renal sinus fat on glomerular cells is reversed by the hepatokine fetuin-A.Scientific reports · 2017Article
- 'Adipaging': ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue.The Journal of physiology · 2016Review
- Low-Energy Shockwave Treatment Promotes Endothelial Progenitor Cell Homing to the Stenotic Pig Kidney.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Obesity remains a prominent public health concern. Obesity not only contributes greatly to cardiovascular events but has also been identified to initiate and affect the progression of preexisting chronic kidney disease. The prevalence of renal artery stenosis is growing world-wide, especially in the elderly population and in individuals with atherosclerotic risk factors such as obesity. Prolonged renovascular disease causes inflammation and microvascular remodeling within the post-stenotic kidney, which promote tissue scarring and may account for irreversible renal damage. Obesity has been shown to aggravate kidney damage via several pathways, including exacerbation of microvascular regression and renal cell injury mediated by adipocytes and insulin resistance, thereby worsening the structural and functional outcomes of the kidney in renovascular disease. Dietary modification and inhibition of the renin-angiotensin-aldosterone system have been shown to alleviate obesity-induced tissue injury and remodeling. Possibly, angiogenic factors may boost microvascular repair in the ischemic kidney in the obesity milieu. Novel therapeutic interventions targeting deleterious pathways that are activated by obesity and responsible for kidney damage need to be explored in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.